



March 11, 2013

## **ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th**

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 25<sup>th</sup> Annual ROTH Conference on Monday, March 18, 2013 at 1:30 pm PT at the Ritz-Carlton, Laguna Niguel, CA.

To access the live audio webcast of the ROTH presentation, please log on through a link located in the Investors section of ImmunoCellular's website at [www.imuc.com](http://www.imuc.com), under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

For ImmunoCellular Therapeutics, Ltd.  
Jane Green  
Investor Relations  
415.348.0010  
[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

Source: ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media